Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Interim results from a first-in-human study with GSK-461364 in advanced solid tumor patients

Oct. 28, 2008

FDA approves Alchemia's IND application for phase III clinical trials of HyCAMP

Oct. 27, 2008

Activity of potent PI3K inhibitor GSK-615 disclosed

Oct. 27, 2008

Calando completes phase I clinical study of IT-101 in inoperable or metastatic tumors

Oct. 27, 2008

Activity of anticancer CDK inhibitor AZD-5597 described

Oct. 27, 2008

Anti-VEGFR-1 monoclonal antibody IMC-18F1 well tolerated thus far in phase I study

Oct. 27, 2008

Early results from first clinical study of JNJ-26854165 reported

Oct. 27, 2008

NMS and Genentech sign collaboration agreement for antibody drug conjugates in cancer

Oct. 24, 2008

Activity seen with OSI-930 in phase I study in solid tumor patients

Oct. 24, 2008

Bendamustine-rituximab combination active in relapsed mantle cell and indolent B-cell lymphoma

Oct. 24, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...